Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Written by Ruchika Sharma Published On 2025-07-05T11:57:34+05:30 | Updated On 5 July 2025 11:57 AM IST

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

New Delhi: US-based Private investment firm Bain Capital has pared down its stake in Emcure Pharmaceuticals, offloading a 2.4 percent holding in the company for Rs 563 crore through an open market transaction.

Following the sale, Bain Capital’s shareholding in Emcure dropped from 8.68 percent to 6.31 percent, PTI reported.

According to bulk deal data from the National Stock Exchange (NSE), Bain Capital, acting through its BC Investments IV, sold 45 lakh shares of Emcure Pharmaceuticals at an average price of Rs 1,250.44 apiece. The total transaction value stood at Rs 562.7 crore.

Details of the buyers of Emcure Pharmaceuticals' shares could not be ascertained on the exchange.

In May, Emcure reported a 63 per cent rise in consolidated profit after tax (PAT) to Rs 197 crore during the March quarter.

It reported a PAT of Rs 121 crore on a consolidated basis a year ago.

During the January-March period, Emcure Pharmaceuticals' revenue from operations stood at Rs 2,116 crore, up 19.5 per cent year-on-year from Rs 1,771 crore.

Emcure's domestic business grew 24.8 per cent year-on-year, led by its women's health and cardio franchises. Meanwhile, the international business registered a growth of 15.6 per cent.

In July last year, Emcure's IPO received a stellar response from institutional buyers by garnering 67.87 times subscription.

Pune-based Emcure Pharmaceuticals is engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Medical Dialogues team earlier reported in June that Emcure Pharma had also received board approval to enter into agreement with minority shareholders of Zuventus Healthcare Ltd., one of its subsidiaries, to acquire their shareholding. Following the completion of this transaction, Zuventus will become a wholly owned subsidiary of Emcure.

Additionally, in April 2025, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited.

bain capitalemcure pharmaemcure pharma newsBC Investments IV

Source : with inputs

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751